



UNITYPOINT HEALTH - MERITER LABORATORIES
TEST ANNOUNCEMENT

**Benzodiazepines Assay Update:
Improved Detection of Glucuronidated Benzodiazepines**

10/3/2023

Effective 10/16/2023, UPH – Meriter Laboratories is updating the in-house Benzodiazepines assay method to include Improved Detection of Glucuronidated Benzodiazepines.

Test Name: Benzodiazepines – Included in Urine Drug of Abuse Panels
Epic EAP: LAB5054, LAB5057, LAB5056
SQ Code: DAUP, UDP8, UDP6
CPT: 80307

Current Benzodiazepines Assay (BENZ):	New Benzodiazepines Assay (BNZ2):
Cutoff index: 200 ng/mL Low to no detection of most glucuronidated benzodiazepines.	Cutoff index: 200 ng/mL Glucuronidated benzodiazepines now detected: <ul style="list-style-type: none">• Oxazepam: 74% cross-reactivity• Temazepam: 63% cross-reactivity• Lorazepam: 56% cross-reactivity

If you have any questions, please call the UnityPoint Health - Meriter Laboratories Client Services Department at 608-417-6529 or 1-800-236-0465.